<DOC>
	<DOCNO>NCT00319735</DOCNO>
	<brief_summary>The interaction epidermal growth factor receptor ( EGFR ) inhibitory agent cetuximab combine radiation show promise result . EGFR inhibitory agent also enhance radiation-induced apoptosis inhibit radiation induce damage repair . These interaction may represent principle effect contribute synergy EGFR radiation . This trial investigate feasibility activity combination patient surgically resectable disease .</brief_summary>
	<brief_title>Cetuximab Radiation Therapy Surgically Resectable Esophageal Gastroesophageal ( GE ) Junction Carcinomas</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Cetuximab 400 mg/m2 IV 120 minute Day -14 ( Loading Dose ) - Cetuximab 250 mg/m2 IV 60 minute , day -7 . - Cetuximab 250 mg/m2 IV 60 minute , day 1 , 8 , 15 , 22 , 29 36 . - External beam radiation therapy , begin day 1 , 4500 cGy esophagus boost 540 cGy 180 cGy per fraction 6 week . - Surgical resection primary tumor adjacent mediastinal and/or celiac lymph node transthoracic approach satisfactory hematologic functional recovery within 8 week completion radiation therapy . - For patient give consent , fresh frozen tissue obtain per EUS baseline , per EUS 2 week initiation cetuximab , time surgery pathology submission .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Pathological diagnosis either squamous cell carcinoma adenocarcinoma esophagus gastroesophageal junction . Clinical stage IIA , IIB III without metastatic disease Patients must document EGFR status tumor tissue available assessment EGFR status IHC Patients must surgical candidate determine surgical consult . Patients must agree surgery . ECOG performance status 0 2 Absolute neutrophil count ( ANC ) &gt; 1,000 mm3 Platelet count &gt; 75,000 mm3· Hemoglobin &gt; 10g/dL Bilirubin &lt; 2.5 X upper limit normal AST ( SGOT ) ALT ( SGPT ) &lt; 5.0 ´ upper limit normal Creatinine &lt; 2.0 X upper limit normal No history current brain metastasis . No significant history uncontrolled cardiac disease ; i.e . uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction . No history interstitial pneumonitis pulmonary fibrosis , suspicion interstitial pneumonitis pulmonary fibrosis imaging . No concurrent chemotherapy indicate study protocol investigational agent ( ) . No prior use radiation chemotherapy cancer esophagus GE junction No prior therapy specifically directly target EGFR pathway ( kinase inhibitor antibody direct HER family receptor ) . No prior severe infusion reaction monoclonal antibody . No major surgery within 28 day prior register protocol therapy . No clinically significant infection judge treat investigator . No acute hepatitis know HIV . No active malignancy . Negative pregnancy test . No female patient currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>